Introduction On July 21-22, the “Pharmaceutical BD Intellectual Property Due Diligence Practice Forum,” hosted by IP Link, was successfully held in Shanghai. Tang Huadong, partner at Merits & Tree Law Offices, was invited to attend the event and delivered a speech on the topic “BD-Oriented Pharmaceutical IP Due Diligence: Key Risk Identification and Structured Response Determining Transaction Success or Failure.”

(1)This forum focused on core topics such as practical intellectual property due diligence in BD transactions, typical cases, risk identification, and prevention strategies. IP leaders from leading pharmaceutical companies such as Junshi Biological, Chia Tai Tianqing, AstraZeneca, Myway Bio, Simcere Pharmaceuticals, and Hengrui Medicine, as well as partners from well-known law firms like Shengzhi, Hankun, Liu Shen, and Feihan from the US, gathered on site to deliver keynote speeches from the perspectives of enterprise IP management and legal practice.

The forum not only featured keynote speeches but also provided a comprehensive communication platform for guests and the audience through a roundtable forum format.

Drawing on their industry experience, the guests shared their views on hot topics such as IP risk control for pharmaceutical companies going global, intellectual property disputes, and patent traps in cross-border transactions. Participants asked questions on the spot with real-world issues encountered in BD trading, and guests responded instantly based on their own experiences. Clarify the questions and organize your thoughts through Q&A.

(2)
Tang Huadong, partner at Merits & Tree Law Offices, delivered a speech titled “BD-Oriented Pharmaceutical IP Due Diligence: Key Risk Identification and Structured Response Determining Transaction Success or Failure,” covering three aspects: the importance of IP risk management for pharmaceutical companies going global, core risk challenges, and systematic response strategies.

Lawyer Tang systematically reviewed the core logic of intellectual property due diligence in transaction scenarios such as pipeline licensing, cross-border License-in/out, pharmaceutical investment and financing, and technology achievement transformation. Combining real transaction cases, he accurately identified key issues in pharmaceutical BD transactions that are easily overlooked, such as hidden IP risks, ownership dispute loopholes, and cross-border compliance traps.
In addition, he combined the current industry trends of normalized cross-border transactions in the biopharmaceutical industry, rapid pipeline iteration, and stricter compliance supervision. At the same time, he provided practical strategies and practical recommendations for the differences in due diligence across various segments such as innovative drugs, biopharmaceuticals, and medical devices.
The entire session closely followed the real scenarios of pharmaceutical BD transactions and featured highly practical cases, addressing the core challenges of IP risk control for pharmaceutical companies going global, and providing attendees with a replicable and practical management and due diligence system for pharmaceutical overseas IP. Guests at the event expressed that this sharing session effectively addressed IP risk control shortcomings in cross-border transactions, providing strong guidance for subsequent pipeline overseas expansion, BD cooperation, and MNC matchmaking.

After the speech, Lawyer Tang Huadong engaged in in-depth discussions with guests on site, pharmaceutical companies, and law firm partners, further discussing topics such as the challenges of IP due diligence in BD transactions and risk prevention strategies. Through cross-sector, multi-perspective professional engagement, all parties formed a more systematic understanding of IP due diligence practices in pharmaceutical BD transactions, accumulating valuable experience for risk identification and response in subsequent cross-border transactions.

(3)

The successful hosting of this practical forum precisely meets the core needs for high-quality development of the biopharmaceutical industry, focusing on the core track of pharmaceutical BD intellectual property transactions, breaking down barriers among industry, capital, law, and services, and providing a high-quality platform for industry practitioners to learn and exchange, connect resources, and share experiences.

MeritsIP and Merits & Tree Law Offices will continue to focus on core tracks such as cross-border biopharmaceutical IP, BD transactions, achievement transformation, and industrial investment and financing, consistently delivering systematic practical content and professional legal services, empowering more pharmaceutical companies to establish stable global layouts and supporting high-quality innovation and development in the industry.

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.